Hyperammonemia
Ammonia
Hyperargininemia
Ornithine Carbamoyltransferase Deficiency Disease
Citrullinemia
Sodium Benzoate
Urea Cycle Disorders, Inborn
Argininosuccinic Aciduria
Amino Acid Metabolism, Inborn Errors
Carbonic Anhydrase V
Argininosuccinic Acid
Methionine Sulfoximine
Hepatic Encephalopathy
Amino-Acid N-Acetyltransferase
Ornithine Carbamoyltransferase
Orotic Acid
Argininosuccinate Synthase
Carbamoyl-Phosphate Synthase I Deficiency Disease
Glutamine
Benzoic Acid
Citrulline
Glutamate Dehydrogenase
Lethargy
Reye Syndrome
Urea
Glutamate-Ammonia Ligase
Metabolism, Inborn Errors
Portacaval Shunt, Surgical
Carbamoyl-Phosphate Synthase (Ammonia)
Carnitine
Argininosuccinate Lyase
Methylmalonic Acid
Acetates
Malonates
Hyperinsulinism
Arginase
Liver Failure
Hyperammonemia after high-dose chemotherapy and stem cell transplantation. (1/122)
We report a patient with multiple myeloma who suffered from hyperammonemia after a second stem cell autograft. This syndrome is not well known but is associated with a high mortality rate. Considering the possibility of this diagnosis in patients developing confusion and neurological degradation with respiratory alkalosis after intensive chemotherapy, could allow earlier treatment and perhaps improved survival. Possible mechanisms and potential therapies are discussed. With rapid recognition and treatment of the syndrome, the patient fully recovered. One and a half years later, she is still alive and well, on interferon for persisting myeloma. (+info)Hyperammonemia with reduced ornithine, citrulline, arginine and proline: a new inborn error caused by a mutation in the gene encoding delta(1)-pyrroline-5-carboxylate synthase. (2/122)
delta(1)-pyrroline-5-carboxylate synthase (P5CS), a bifunctional ATP- and NADPH-dependent mitochondrial enzyme, catalyzes the reduction of glutamate to delta(1)-pyrroline-5-carboxylate, a critical step in the biosynthesis of proline, ornithine and arginine. Recently, we reported the cloning and expression of human and murine P5CS cDNAs. Previously, we showed that mammalian P5CS undergoes alternative splicing to generate two isoforms differing only by a 2 amino acid insert at the N-terminus of the gamma-glutamyl kinase active site. The short isoform has high activity in the gut, where it participates in arginine biosynthesis and is inhibited by ornithine. The long isoform, expressed in multiple tissues, is necessary for the synthesis of proline from glutamate and is insensitive to ornithine. Here, we describe a newly recognized inborn error due to the deficiency of P5CS in two siblings with progressive neurodegeneration, joint laxity, skin hyperelasticity and bilateral subcapsular cataracts. Their metabolic phenotype includes hyperammonemia, hypoornithinemia, hypocitrullinemia, hypoargininemia and hypoprolinemia. Both are homozygous for the missense mutation, R84Q, which alters a conserved residue in the P5CS gamma-glutamyl kinase domain. R84Q is not present in 194 control chromosomes and dramatically reduces the activity of both P5CS isoforms when expressed in mammalian cells. Additionally, R84Q appears to destabilize the long isoform. This is the first documented report of an inborn error of P5CS and suggests that this disorder should be considered in the differential diagnosis in patients with neurodegeneration and/or cataracts and connective tissue disease. (+info)Helicobacter pylori infection induces hyperammonaemia in Mongolian gerbils with liver cirrhosis. (3/122)
BACKGROUND AND AIMS: We previously reported the effect of Helicobacter pylori eradication on hyperammonaemia in patients with liver cirrhosis. However, the role of H pylori as a cause of hyperammonaemia is controversial. We developed an animal model with liver cirrhosis and investigated the effect of H pylori infection on hyperammonaemia. MATERIALS AND METHODS: Five week old male Mongolian gerbils were inoculated orally with broth culture of H pylori. Forty eight gerbils were divided into four groups. Gerbils not inoculated with H pylori were fed a commercial rodent diet (group A) or a choline deficient diet (group C). Gerbils inoculated with H pylori were fed the commercial rodent diet (group B) or the choline deficient diet (group D). Blood ammonia levels of the femoral vein and portal vein were measured 30 weeks later. RESULTS: All gerbils fed the choline deficient diet developed liver cirrhosis with fatty metamorphosis. The survival rate of group D was significantly lower than that of the other groups. Systemic and portal blood ammonia levels in group D were significantly higher than those in the other groups. CONCLUSIONS: H pylori infection induces hyperammonaemia in gerbils with liver cirrhosis. (+info)Hepatic mitochondrial proteins in congenitally hyperammonemic spf mice: effect of acetyl-L-carnitine. (4/122)
The sparse-fur (spf) mutant mouse has an X-linked deficiency of hepatic ornithine transcarbamylase (OTC), and develops hyperammonemia immediately after weaning and maintains it throughout its life span. We have studied the effects of acetyl-L-carnitine (ALCAR) on the hepatic mitochondrial proteins of the chronically hyperammonemic spf mice. Two different age groups of mice were studied, the weanlings (3 weeks) and the adult mice (8 weeks). Our results indicate that in the mitochondrial matrix, the untreated chronic hyperammonemia induced a significant increase in the quantity of 54.4-kDa protein in spf adult mice. After ALCAR treatment, in spf adult mice, the quantities of the 54.4-kDa, 63.8-kDa, and 129-kDa matrix proteins were significantly increased. In the mitochondrial inner membrane fraction of the spf weanling mice, a 53.5-kDa protein was significantly increased by ALCAR treatment. Our results show that: (a) chronic hyperammonemia has altered the mitochondrial matrix protein profile in spf mice, that (b) ALCAR has a modulating effect on various matrix and inner membrane proteins, and that (c) there was no effect of hyperammonemia or ALCAR treatment on the outer membrane proteins. (+info)Short report: Hyperammonaemia in critically ill septic infants. (5/122)
Three infants with subphrenic abscess, pyonephrosis, and obstructive ureterocoele respectively had grossly increased concentrations of plasma ammonia. This was considered to be a result of infections with urea splitting organisms. All died in spite of intensive care support, including specific measures to reduce plasma ammonia. (+info)Acute insulin responses to leucine in children with the hyperinsulinism/hyperammonemia syndrome. (6/122)
Mutations of glutamate dehydrogenase cause the hyperinsulinism/hyperammonemia syndrome by desensitizing glutamate dehydrogenase to allosteric inhibition by GTP. Normal allosteric activation of glutamate dehydrogenase by leucine is thus uninhibited, leading us to propose that children with hyperinsulinism/hyperammonemia syndrome will have exaggerated acute insulin responses to leucine in the postabsorptive state. As hyperglycemia increases beta-cell GTP, we also postulated that high glucose concentrations would extinguish abnormal responsiveness to leucine in hyperinsulinism/hyperammonemia syndrome patients. After an overnight fast, seven hyperinsulinism/hyperammonemia syndrome patients (aged 9 months to 29 yr) had acute insulin responses to leucine performed using an iv bolus of L-leucine (15 mg/kg) administered over 1 min and plasma insulin measurements obtained at -10, -5, 0, 1, 3, and 5 min. The acute insulin response to leucine was defined as the mean increase in insulin from baseline at 1 and 3 min after an iv leucine bolus. The hyperinsulinism/hyperammonemia syndrome group had excessively increased insulin responses to leucine (mean +/- SEM, 73 +/- 21 microIU/ml) compared with the control children and adults (n = 17) who had no response to leucine (1.9 +/- 2.7 microU/ml; P < 0.05). Four hyperinsulinism/hyperammonemia syndrome patients then had acute insulin responses to leucine repeated at hyperglycemia (blood glucose, 150-180 mg/dl). High blood glucose suppressed their abnormal baseline acute insulin responses to leucine of 180, 98, 47, and 28 microU/ml to 73, 0, 6, and 19 microU/ml, respectively. This suppression suggests that protein-induced hypoglycemia in hyperinsulinism/hyperammonemia syndrome patients may be prevented by carbohydrate loading before protein consumption. (+info)In vivo nuclear magnetic resonance studies of glutamate-gamma-aminobutyric acid-glutamine cycling in rodent and human cortex: the central role of glutamine. (7/122)
It has been recognized for many years that the metabolism of brain glutamate and gamma-aminobutyric acid (GABA), the major excitatory and inhibitory neurotransmitters, is linked to a substrate cycle between neurons and astrocytes involving glutamine. However, the quantitative significance of these fluxes in vivo was not known. Recent in vivo 13C and 15N NMR studies in rodents and 13C NMR in humans indicate that glutamine synthesis is substantial and that the total glutamate-GABA-glutamine cycling flux, necessary to replenish neurotransmitter glutamate and GABA, accounts for >80% of net glutamine synthesis. In studies of the rodent cortex, a linear relationship exists between the rate of glucose oxidation and total glutamate-GABA-glutamine cycling flux over a large range of cortical electrical activity. The molar stoichiometric relationship (approximately 1:1) found between these fluxes suggests that they share a common mechanism and that the glutamate-GABA-glutamine cycle is coupled to a major fraction of cortical glucose utilization. Thus, glutamine appears to play a central role in the normal functional energetics of the cerebral cortex. (+info)Non-hepatic hyperammonaemia: an important, potentially reversible cause of encephalopathy. (8/122)
The clinical syndrome of encephalopathy is most often encountered in the context of decompensated liver disease and the diagnosis is usually clear cut. Non-hepatic causes of encephalopathy are rarer and tend to present to a wide range of medical specialties with variable and episodic symptoms. Delay can result in the development of potentially life threatening complications, such as seizures and coma. Early recognition is vital. A history of similar episodes or clinical risk factors and early assessment of blood ammonia levels help establish the diagnosis. In addition to adequate supportive care, investigation of the underlying cause of the hyperammonaemia is essential and its reversal, where possible, will often result in complete recovery. Detection of an unborn error of metabolism should lead to the initiation of appropriate maintenance therapy and genetic counselling. (+info)Hyperammonemia is a medical condition characterized by an excessively high level of ammonia (a toxic byproduct of protein metabolism) in the blood. This can lead to serious neurological symptoms and complications, as ammonia is highly toxic to the brain. Hyperammonemia can be caused by various underlying conditions, including liver disease, genetic disorders that affect ammonia metabolism, certain medications, and infections. It is important to diagnose and treat hyperammonemia promptly to prevent long-term neurological damage or even death. Treatment typically involves addressing the underlying cause of the condition, as well as providing supportive care such as administering medications that help remove ammonia from the blood.
Ammonia is a colorless, pungent-smelling gas with the chemical formula NH3. It is a compound of nitrogen and hydrogen and is a basic compound, meaning it has a pH greater than 7. Ammonia is naturally found in the environment and is produced by the breakdown of organic matter, such as animal waste and decomposing plants. In the medical field, ammonia is most commonly discussed in relation to its role in human metabolism and its potential toxicity.
In the body, ammonia is produced as a byproduct of protein metabolism and is typically converted to urea in the liver and excreted in the urine. However, if the liver is not functioning properly or if there is an excess of protein in the diet, ammonia can accumulate in the blood and cause a condition called hyperammonemia. Hyperammonemia can lead to serious neurological symptoms, such as confusion, seizures, and coma, and is treated by lowering the level of ammonia in the blood through medications, dietary changes, and dialysis.
Hyperargininemia is a rare genetic disorder characterized by an excess of arginine in the blood. Arginine is an amino acid, which are the building blocks of proteins. In hyperargininemia, there is a deficiency or dysfunction of the enzyme argininosuccinate synthetase, leading to an accumulation of arginine and related compounds in the body. This can cause various symptoms such as intellectual disability, seizures, spasticity, and feeding difficulties. It is inherited in an autosomal recessive manner, meaning that an individual must receive two copies of the defective gene (one from each parent) to develop the condition.
Ornithine Carbamoyltransferase (OCT) Deficiency Disease, also known as Ornithine Transcarbamylase Deficiency, is a rare inherited urea cycle disorder. It is caused by a deficiency of the enzyme ornithine carbamoyltransferase, which is responsible for one of the steps in the urea cycle that helps to rid the body of excess nitrogen (in the form of ammonia).
When OCT function is impaired, nitrogen accumulates and forms ammonia, leading to hyperammonemia (elevated blood ammonia levels), which can cause neurological symptoms such as lethargy, vomiting, irritability, and in severe cases, coma or death.
Symptoms of OCT deficiency can range from mild to severe and may include developmental delay, seizures, behavioral changes, and movement disorders. The diagnosis is typically made through newborn screening tests, enzyme assays, and genetic testing. Treatment usually involves a combination of dietary restrictions, medications that help remove nitrogen from the body, and in some cases, liver transplantation.
Citrullinemia is a rare inherited metabolic disorder characterized by the body's inability to properly process and eliminate certain toxic byproducts that are generated during the breakdown of proteins. This condition results from a deficiency of the enzyme argininosuccinate synthetase, which is required for the normal functioning of the urea cycle. The urea cycle is a series of biochemical reactions that occur in the liver and help to convert ammonia, a toxic substance, into urea, which can then be excreted by the kidneys.
There are two main types of citrullinemia: type I (also known as classic citrullinemia) and type II (also known as citrullinemia type II or adult-onset citrullinemia). Type I is typically more severe and can present in newborns with symptoms such as poor feeding, vomiting, seizures, and developmental delays. If left untreated, it can lead to serious complications, including intellectual disability, coma, and even death.
Type II citrullinemia, on the other hand, tends to present later in life, often in adulthood, and may cause symptoms such as confusion, seizures, and neurological problems. It is important to note that some individuals with type II citrullinemia may never develop any symptoms at all.
Treatment for citrullinemia typically involves a combination of dietary restrictions, supplements, and medications to help manage the buildup of toxic byproducts in the body. In severe cases, liver transplantation may be considered as a last resort.
Sodium benzoate is a chemical compound with the formula NaC7H5O2. It is a white crystalline powder that is readily soluble in water and alcohol. Sodium benzoate is a preservative commonly added to foods, beverages, and pharmaceuticals to inhibit microbial growth.
In medical terms, sodium benzoate may also be used as a medication to treat certain metabolic disorders such as hyperammonemia, which can occur in conditions like urea cycle disorders or liver disease. In these cases, sodium benzoate acts by binding with excess ammonia in the body and converting it into a compound that can be excreted through the kidneys.
It is important to note that people with a rare genetic disorder called benzoic aciduria should avoid foods or medications containing sodium benzoate, as they are unable to metabolize this compound properly.
Inborn urea cycle disorders (UCDs) are a group of rare genetic metabolic disorders caused by deficiencies in one of the enzymes or transporters that make up the urea cycle. The urea cycle is a series of biochemical reactions that occur in liver cells, responsible for removing ammonia, a toxic byproduct of protein metabolism, from the bloodstream.
In UCDs, the impaired function of these enzymes or transporters leads to an accumulation of ammonia in the blood (hyperammonemia), which can cause irreversible brain damage and severe neurological symptoms if left untreated. These disorders are usually inherited in an autosomal recessive manner, meaning that an affected individual has two copies of the mutated gene, one from each parent.
There are six main types of UCDs, classified based on the specific enzyme or transporter deficiency:
1. Carbamoyl phosphate synthetase I (CPS1) deficiency
2. Ornithine transcarbamylase (OTC) deficiency
3. Argininosuccinic aciduria (ASA)
4. Citrullinemia type I or II (CTLN1, CTLN2)
5. Arginase deficiency
6. N-acetylglutamate synthetase (NAGS) deficiency
Symptoms of UCDs can vary widely depending on the severity and specific type of the disorder but may include:
* Vomiting
* Lethargy or irritability
* Seizures
* Tremors or seizure-like activity
* Developmental delays or intellectual disability
* Coma
Early diagnosis and treatment are crucial to prevent long-term neurological damage. Treatment options include dietary restrictions, medications that help remove ammonia from the body, and liver transplantation in severe cases. Regular monitoring of blood ammonia levels and other metabolic markers is essential for managing UCDs effectively.
Argininosuccinic aciduria (ASA) is a rare inherited metabolic disorder caused by a deficiency of the enzyme argininosuccinate lyase. This enzyme is necessary for the urea cycle, a process that helps rid the body of excess nitrogen produced from protein breakdown. When the urea cycle is not functioning properly, nitrogen accumulates in the form of ammonia, which can be toxic to the brain and other organs.
In ASA, argininosuccinic acid builds up in the blood and urine, giving the condition its name. Symptoms of ASA typically appear within the first few days or weeks of life and may include poor feeding, vomiting, lethargy, seizures, and developmental delay. If left untreated, ASA can lead to serious complications such as intellectual disability, coma, and even death.
Treatment for ASA usually involves a combination of dietary restrictions, medications to reduce ammonia levels, and supplementation with arginine, an amino acid that is not properly metabolized in people with ASA. In some cases, liver transplantation may be necessary. Early diagnosis and treatment are crucial for improving outcomes in individuals with ASA.
Inborn errors of amino acid metabolism refer to genetic disorders that affect the body's ability to properly break down and process individual amino acids, which are the building blocks of proteins. These disorders can result in an accumulation of toxic levels of certain amino acids or their byproducts in the body, leading to a variety of symptoms and health complications.
There are many different types of inborn errors of amino acid metabolism, each affecting a specific amino acid or group of amino acids. Some examples include:
* Phenylketonuria (PKU): This disorder affects the breakdown of the amino acid phenylalanine, leading to its accumulation in the body and causing brain damage if left untreated.
* Maple syrup urine disease: This disorder affects the breakdown of the branched-chain amino acids leucine, isoleucine, and valine, leading to their accumulation in the body and causing neurological problems.
* Homocystinuria: This disorder affects the breakdown of the amino acid methionine, leading to its accumulation in the body and causing a range of symptoms including developmental delay, intellectual disability, and cardiovascular problems.
Treatment for inborn errors of amino acid metabolism typically involves dietary restrictions or supplementation to manage the levels of affected amino acids in the body. In some cases, medication or other therapies may also be necessary. Early diagnosis and treatment can help prevent or minimize the severity of symptoms and health complications associated with these disorders.
I apologize, but there seems to be no medical definition for "Carbonic Anhydrase V." Carbonic anhydrases are a family of enzymes that catalyze the reversible hydration of carbon dioxide to form bicarbonate and protons. There are several isoforms of carbonic anhydrase (CA I-IV, CA VI-VIII, etc.), but as far as current scientific knowledge and literature go, there isn't a recognized or well-established isoform called Carbonic Anhydrase V.
It is possible that you may have encountered a mistake or typographical error in your source material. If you have more context or information about where you found this term, I would be happy to help you further research the topic.
Argininosuccinic acid is a chemical compound that is an intermediate in the metabolic pathway for the synthesis of arginine, an essential amino acid. This process occurs in the urea cycle, which is responsible for removing excess nitrogen from the body in the form of urea.
In the urea cycle, citrulline reacts with aspartate to form argininosuccinic acid, which is then converted into arginine and fumarate by the enzyme argininosuccinate lyase. Arginine is a semi-essential amino acid that plays important roles in various physiological processes, including protein synthesis, nitric oxide production, and hormone secretion.
Argininosuccinic aciduria is a rare inherited metabolic disorder caused by a deficiency of the enzyme argininosuccinate lyase. This results in an accumulation of argininosuccinic acid in the blood and urine, leading to hyperammonemia (elevated levels of ammonia in the blood), neurological symptoms, and developmental delay. Treatment typically involves a low-protein diet, supplementation with arginine and citrulline, and nitrogen scavenging medications to reduce ammonia levels.
Methionine Sulfoximine (MSO) is not a medical term itself, but it is a compound that has been used in research and scientific studies. It's a stable analogue of the essential amino acid methionine, which can be found in some foods like sesame seeds, Brazil nuts, and fish.
Methionine Sulfoximine has been used in research to study the metabolism and transport of methionine in cells and organisms. It is also known for its ability to inhibit the enzyme cystathionine β-synthase (CBS), which plays a role in the metabolism of homocysteine, an amino acid associated with cardiovascular disease when present at high levels.
However, Methionine Sulfoximine is not used as a therapeutic agent or medication in humans due to its potential toxicity and lack of established clinical benefits.
Hepatic encephalopathy (HE) is a neuropsychiatric syndrome associated with liver dysfunction and/or portosystemic shunting. It results from the accumulation of toxic substances, such as ammonia and inflammatory mediators, which are normally metabolized by the liver. HE can present with a wide range of symptoms, including changes in sleep-wake cycle, altered mental status, confusion, disorientation, asterixis (flapping tremor), and in severe cases, coma. The diagnosis is based on clinical evaluation, neuropsychological testing, and exclusion of other causes of cognitive impairment. Treatment typically involves addressing the underlying liver dysfunction, reducing ammonia production through dietary modifications and medications, and preventing further episodes with lactulose or rifaximin therapy.
Amino-acid N-acetyltransferases are a group of enzymes that catalyze the transfer of an acetyl group from acetyl coenzyme A to the amino group of an amino acid. This modification can have various effects on the function and stability of the modified amino acid, and plays a role in several cellular processes, including protein synthesis, degradation, and post-translational modification.
The systematic name for this enzyme class is "acetyl-CoA:amino-acid N-acetyltransferase". They are classified under the EC number 2.3.1. acetyltransferases. There are several subtypes of amino-acid N-acetyltransferases, each with specificity for certain amino acids or groups of amino acids.
These enzymes play a role in various biological processes such as:
* Protein synthesis and folding
* Degradation of amino acids and proteins
* Regulation of gene expression
* Detoxification of xenobiotics (foreign substances)
Defects or mutations in genes encoding for these enzymes can lead to various diseases, such as neurological disorders and cancer.
Ornithine carbamoyltransferase (OCT or OAT) is an enzyme that plays a crucial role in the urea cycle, which is the biochemical pathway responsible for the removal of excess nitrogen from the body. Specifically, ornithine carbamoyltransferase catalyzes the transfer of a carbamoyl group from carbamoyl phosphate to ornithine, forming citrulline and releasing phosphate in the process. This reaction is essential for the production of urea, which can then be excreted by the kidneys.
Deficiency in ornithine carbamoyltransferase can lead to a genetic disorder called ornithine transcarbamylase deficiency (OTCD), which is characterized by hyperammonemia (elevated blood ammonia levels) and neurological symptoms. OTCD is one of the most common urea cycle disorders, and it primarily affects females due to its X-linked inheritance pattern.
Orotic acid, also known as pyrmidine carboxylic acid, is a organic compound that plays a role in the metabolic pathway for the biosynthesis of pyrimidines, which are nitrogenous bases found in nucleotides and nucleic acids such as DNA and RNA. Orotic acid is not considered to be a vitamin, but it is sometimes referred to as vitamin B13 or B15, although these designations are not widely recognized by the scientific community.
In the body, orotic acid is converted into orotidine monophosphate (OMP) by the enzyme orotate phosphoribosyltransferase. OMP is then further metabolized to form uridine monophosphate (UMP), a pyrimidine nucleotide that is an important precursor for the synthesis of RNA and other molecules.
Elevated levels of orotic acid in the urine, known as orotic aciduria, can be a sign of certain genetic disorders that affect the metabolism of pyrimidines. These conditions can lead to an accumulation of orotic acid and other pyrimidine precursors in the body, which can cause a range of symptoms including developmental delays, neurological problems, and kidney stones. Treatment for these disorders typically involves dietary restrictions and supplementation with nucleotides or nucleosides to help support normal pyrimidine metabolism.
Aspartate aminotransferase (AST), mitochondrial isoform, is an enzyme found primarily in the mitochondria of cells. It is involved in the transfer of an amino group from aspartic acid to alpha-ketoglutarate, resulting in the formation of oxaloacetate and glutamate. This enzyme plays a crucial role in the cellular energy production process, particularly within the mitochondria.
Elevated levels of AST, mitochondrial isoform, can be found in various medical conditions, including liver disease, muscle damage, and heart injury. However, it's important to note that most clinical laboratories measure a combined level of both cytosolic and mitochondrial AST isoforms when testing for this enzyme. Therefore, the specific contribution of the mitochondrial isoform may not be easily discernible in routine medical tests.
Argininosuccinate synthase (ASS) is a urea cycle enzyme that plays a crucial role in the detoxification of ammonia in the body. This enzyme catalyzes the reaction that combines citrulline and aspartate to form argininosuccinate, which is subsequently converted to arginine and fumarate in the urea cycle.
The reaction catalyzed by argininosuccinate synthase is as follows:
Citrulline + Aspartate + ATP → Argininosuccinate + AMP + PPi
Deficiency in argininosuccinate synthase leads to a genetic disorder known as citrullinemia, which is characterized by an accumulation of ammonia in the blood and neurodevelopmental abnormalities. There are two forms of citrullinemia, type I and type II, with type I being more severe and caused by mutations in the ASS1 gene located on chromosome 9q34.
Carbamoyl-phosphate synthase I (CPS1) deficiency disease is a rare inherited disorder of urea synthesis, which can lead to hyperammonemia (elevated blood ammonia levels) and life-threatening neurological symptoms. CPS1 is an enzyme that plays a crucial role in the first step of the urea cycle, where it catalyzes the conversion of ammonia and bicarbonate into carbamoyl phosphate.
In CPS1 deficiency disease, mutations in the CPS1 gene lead to reduced or absent enzyme activity, impairing the body's ability to detoxify ammonia. As a result, toxic levels of ammonia accumulate in the blood and can cause irreversible brain damage, intellectual disability, coma, or even death if not treated promptly and effectively.
Symptoms of CPS1 deficiency disease may include poor feeding, vomiting, lethargy, hypotonia (low muscle tone), seizures, and developmental delays. The severity of the disorder can vary widely, from a severe neonatal-onset form with early symptoms appearing within the first few days of life to a milder late-onset form that may not become apparent until later in infancy or childhood.
Treatment typically involves a combination of dietary restrictions, medications to lower ammonia levels and support liver function, and, in some cases, liver transplantation. Early diagnosis and intervention are critical for improving outcomes and minimizing the risk of long-term neurological complications.
Glutamine is defined as a conditionally essential amino acid in humans, which means that it can be produced by the body under normal circumstances, but may become essential during certain conditions such as stress, illness, or injury. It is the most abundant free amino acid found in the blood and in the muscles of the body.
Glutamine plays a crucial role in various biological processes, including protein synthesis, energy production, and acid-base balance. It serves as an important fuel source for cells in the intestines, immune system, and skeletal muscles. Glutamine has also been shown to have potential benefits in wound healing, gut function, and immunity, particularly during times of physiological stress or illness.
In summary, glutamine is a vital amino acid that plays a critical role in maintaining the health and function of various tissues and organs in the body.
Benzoic acid is an organic compound with the formula C6H5COOH. It is a colorless crystalline solid that is slightly soluble in water and more soluble in organic solvents. Benzoic acid occurs naturally in various plants and serves as an intermediate in the synthesis of other chemical compounds.
In medical terms, benzoic acid and its salts (sodium benzoate, potassium benzoate) are used as preservatives in food, beverages, and cosmetics to prevent bacterial growth. They work by inhibiting the growth of bacteria, particularly gram-positive bacteria, through the disruption of their energy production processes.
Additionally, sodium benzoate is sometimes used as a treatment for hyperammonemia, a condition characterized by high levels of ammonia in the blood. In this case, sodium benzoate acts as a detoxifying agent by binding to excess ammonia and converting it into a more easily excreted compound called hippuric acid.
It is important to note that benzoic acid and its salts can cause allergic reactions or skin irritation in some individuals, particularly those with pre-existing sensitivities or conditions. As with any medication or chemical substance, it should be used under the guidance of a healthcare professional.
L-Citrulline is a non-essential amino acid that plays a role in the urea cycle, which is the process by which the body eliminates toxic ammonia from the bloodstream. It is called "non-essential" because it can be synthesized by the body from other compounds, such as L-Ornithine and carbamoyl phosphate.
Citrulline is found in some foods, including watermelon, bitter melon, and certain types of sausage. It is also available as a dietary supplement. In the body, citrulline is converted to another amino acid called L-Arginine, which is involved in the production of nitric oxide, a molecule that helps dilate blood vessels and improve blood flow.
Citrulline has been studied for its potential benefits on various aspects of health, including exercise performance, cardiovascular function, and immune system function. However, more research is needed to confirm these potential benefits and establish safe and effective dosages.
Glutamate Dehydrogenase (GLDH or GDH) is a mitochondrial enzyme that plays a crucial role in the metabolism of amino acids, particularly within liver and kidney tissues. It catalyzes the reversible oxidative deamination of glutamate to alpha-ketoglutarate, which links amino acid metabolism with the citric acid cycle and energy production. This enzyme is significant in clinical settings as its levels in blood serum can be used as a diagnostic marker for diseases that damage liver or kidney cells, since these cells release GLDH into the bloodstream upon damage.
Lethargy is a state of extreme fatigue, drowsiness, and/or lack of energy. In a medical context, lethargy may refer to a reduced level of consciousness or awareness where an individual has difficulty staying awake or responding to stimuli. It can be a symptom of various medical conditions such as infections, neurological disorders, metabolic imbalances, or psychological issues. However, it is important to note that lethargy should be evaluated by a healthcare professional for proper diagnosis and treatment.
Ornithine is not a medical condition but a naturally occurring alpha-amino acid, which is involved in the urea cycle, a process that eliminates ammonia from the body. Here's a brief medical/biochemical definition of Ornithine:
Ornithine (NH₂-CH₂-CH₂-CH(NH₃)-COOH) is an α-amino acid without a carbon atom attached to the amino group, classified as a non-proteinogenic amino acid because it is not encoded by the standard genetic code and not commonly found in proteins. It plays a crucial role in the urea cycle, where it helps convert harmful ammonia into urea, which can then be excreted by the body through urine. Ornithine is produced from the breakdown of arginine, another amino acid, via the enzyme arginase. In some medical and nutritional contexts, ornithine supplementation may be recommended to support liver function, wound healing, or muscle growth, but its effectiveness for these uses remains a subject of ongoing research and debate.
Reye Syndrome is a rare but serious condition that primarily affects children and teenagers, particularly those who have recently recovered from viral infections such as chickenpox or flu. It is characterized by rapidly progressive encephalopathy (brain dysfunction) and fatty degeneration of the liver.
The exact cause of Reye Syndrome remains unknown, but it has been linked to the use of aspirin and other salicylate-containing medications during viral illnesses. The American Academy of Pediatrics recommends avoiding the use of aspirin in children and teenagers with chickenpox or flu-like symptoms due to this association.
Early symptoms of Reye Syndrome include persistent vomiting, diarrhea, and listlessness. As the condition progresses, symptoms can worsen and may include disorientation, seizures, coma, and even death in severe cases. Diagnosis is typically based on clinical presentation, laboratory tests, and sometimes a liver biopsy.
Treatment for Reye Syndrome involves supportive care, such as fluid and electrolyte management, addressing metabolic abnormalities, controlling intracranial pressure, and providing ventilatory support if necessary. Early recognition and intervention are crucial to improving outcomes in affected individuals.
Urea is not a medical condition but it is a medically relevant substance. Here's the definition:
Urea is a colorless, odorless solid that is the primary nitrogen-containing compound in the urine of mammals. It is a normal metabolic end product that is excreted by the kidneys and is also used as a fertilizer and in various industrial applications. Chemically, urea is a carbamide, consisting of two amino groups (NH2) joined by a carbon atom and having a hydrogen atom and a hydroxyl group (OH) attached to the carbon atom. Urea is produced in the liver as an end product of protein metabolism and is then eliminated from the body by the kidneys through urination. Abnormal levels of urea in the blood, known as uremia, can indicate impaired kidney function or other medical conditions.
Glutamate-ammonia ligase, also known as glutamine synthetase, is an enzyme that plays a crucial role in nitrogen metabolism. It catalyzes the formation of glutamine from glutamate and ammonia in the presence of ATP, resulting in the conversion of ammonia to a less toxic form. This reaction is essential for maintaining nitrogen balance in the body and for the synthesis of various amino acids, nucleotides, and other biomolecules. The enzyme is widely distributed in various tissues, including the brain, liver, and muscle, and its activity is tightly regulated through feedback inhibition by glutamine and other metabolites.
Inborn errors of metabolism (IEM) refer to a group of genetic disorders caused by defects in enzymes or transporters that play a role in the body's metabolic processes. These disorders result in the accumulation or deficiency of specific chemicals within the body, which can lead to various clinical manifestations, such as developmental delay, intellectual disability, seizures, organ damage, and in some cases, death.
Examples of IEM include phenylketonuria (PKU), maple syrup urine disease (MSUD), galactosemia, and glycogen storage diseases, among many others. These disorders are typically inherited in an autosomal recessive manner, meaning that an affected individual has two copies of the mutated gene, one from each parent.
Early diagnosis and management of IEM are crucial to prevent or minimize complications and improve outcomes. Treatment options may include dietary modifications, supplementation with missing enzymes or cofactors, medication, and in some cases, stem cell transplantation or gene therapy.
A portacaval shunt is a surgical procedure that creates an alternate pathway for blood flow between the portal vein and the inferior vena cava. The portal vein carries blood from the gastrointestinal tract, liver, spleen, and pancreas to the liver. In certain medical conditions, such as severe liver disease or portal hypertension, the blood pressure in the portal vein becomes abnormally high, which can lead to serious complications like variceal bleeding.
In a surgical portacaval shunt procedure, a surgeon creates a connection between the portal vein and the inferior vena cava, allowing a portion of the blood from the portal vein to bypass the liver and flow directly into the systemic circulation. This helps reduce the pressure in the portal vein and prevent complications associated with portal hypertension.
There are different types of portacaval shunts, including:
1. Direct portacaval shunt: In this procedure, the surgeon directly connects the portal vein to the inferior vena cava.
2. Side-to-side portacaval shunt: Here, the surgeon creates an anastomosis (connection) between a side branch of the portal vein and the inferior vena cava.
3. H-type shunt: This involves creating two separate connections between the portal vein and the inferior vena cava, forming an "H" shape.
It is important to note that while portacaval shunts can be effective in managing complications of portal hypertension, they may also have potential risks and side effects, such as worsening liver function, encephalopathy, or heart failure. Therefore, the decision to perform a portacaval shunt should be made carefully, considering the individual patient's medical condition and overall health.
Carnitine is a naturally occurring substance in the body that plays a crucial role in energy production. It transports long-chain fatty acids into the mitochondria, where they can be broken down to produce energy. Carnitine is also available as a dietary supplement and is often used to treat or prevent carnitine deficiency.
The medical definition of Carnitine is:
"A quaternary ammonium compound that occurs naturally in animal tissues, especially in muscle, heart, brain, and liver. It is essential for the transport of long-chain fatty acids into the mitochondria, where they can be oxidized to produce energy. Carnitine also functions as an antioxidant and has been studied as a potential treatment for various conditions, including heart disease, diabetes, and kidney disease."
Carnitine is also known as L-carnitine or levocarnitine. It can be found in foods such as red meat, dairy products, fish, poultry, and tempeh. In the body, carnitine is synthesized from the amino acids lysine and methionine with the help of vitamin C and iron. Some people may have a deficiency in carnitine due to genetic factors, malnutrition, or certain medical conditions, such as kidney disease or liver disease. In these cases, supplementation may be necessary to prevent or treat symptoms of carnitine deficiency.
Arginine is an α-amino acid that is classified as a semi-essential or conditionally essential amino acid, depending on the developmental stage and health status of the individual. The adult human body can normally synthesize sufficient amounts of arginine to meet its needs, but there are certain circumstances, such as periods of rapid growth or injury, where the dietary intake of arginine may become necessary.
The chemical formula for arginine is C6H14N4O2. It has a molecular weight of 174.20 g/mol and a pKa value of 12.48. Arginine is a basic amino acid, which means that it contains a side chain with a positive charge at physiological pH levels. The side chain of arginine is composed of a guanidino group, which is a functional group consisting of a nitrogen atom bonded to three methyl groups.
In the body, arginine plays several important roles. It is a precursor for the synthesis of nitric oxide, a molecule that helps regulate blood flow and immune function. Arginine is also involved in the detoxification of ammonia, a waste product produced by the breakdown of proteins. Additionally, arginine can be converted into other amino acids, such as ornithine and citrulline, which are involved in various metabolic processes.
Foods that are good sources of arginine include meat, poultry, fish, dairy products, nuts, seeds, and legumes. Arginine supplements are available and may be used for a variety of purposes, such as improving exercise performance, enhancing wound healing, and boosting immune function. However, it is important to consult with a healthcare provider before taking arginine supplements, as they can interact with certain medications and have potential side effects.
Argininosuccinate Lyase is an enzyme that plays a crucial role in the urea cycle, which is the metabolic pathway responsible for eliminating excess nitrogen waste from the body. This enzyme is responsible for catalyzing the conversion of argininosuccinate into arginine and fumarate.
The urea cycle occurs primarily in the liver and helps to convert toxic ammonia, a byproduct of protein metabolism, into urea, which can be safely excreted in urine. Argininosuccinate lyase is essential for this process, as it helps to convert argininosuccinate, an intermediate compound in the cycle, into arginine, which can then be recycled back into the urea cycle or used for other physiological processes.
Deficiencies in argininosuccinate lyase can lead to a rare genetic disorder known as citrullinemia, which is characterized by elevated levels of citrulline and ammonia in the blood, as well as neurological symptoms such as seizures, developmental delays, and intellectual disability. Treatment for citrullinemia typically involves a low-protein diet, supplementation with arginine and other essential amino acids, and in some cases, liver transplantation.
Methylmalonic acid (MMA) is an organic compound that is produced in the human body during the metabolism of certain amino acids, including methionine and threonine. It is a type of fatty acid that is intermediate in the breakdown of these amino acids in the liver and other tissues.
Under normal circumstances, MMA is quickly converted to succinic acid, which is then used in the Krebs cycle to generate energy in the form of ATP. However, when there are deficiencies or mutations in enzymes involved in this metabolic pathway, such as methylmalonyl-CoA mutase, MMA can accumulate in the body and cause methylmalonic acidemia, a rare genetic disorder that affects approximately 1 in every 50,000 to 100,000 individuals worldwide.
Elevated levels of MMA in the blood or urine can be indicative of various metabolic disorders, including methylmalonic acidemia, vitamin B12 deficiency, and renal insufficiency. Therefore, measuring MMA levels is often used as a diagnostic tool to help identify and manage these conditions.
Acetates, in a medical context, most commonly refer to compounds that contain the acetate group, which is an functional group consisting of a carbon atom bonded to two hydrogen atoms and an oxygen atom (-COO-). An example of an acetate is sodium acetate (CH3COONa), which is a salt formed from acetic acid (CH3COOH) and is often used as a buffering agent in medical solutions.
Acetates can also refer to a group of medications that contain acetate as an active ingredient, such as magnesium acetate, which is used as a laxative, or calcium acetate, which is used to treat high levels of phosphate in the blood.
In addition, acetates can also refer to a process called acetylation, which is the addition of an acetyl group (-COCH3) to a molecule. This process can be important in the metabolism and regulation of various substances within the body.
"Malonates" is not a recognized medical term. However, in chemistry, malonates refer to salts or esters of malonic acid, a dicarboxylic acid with the formula CH2(COOH)2. Malonic acid and its derivatives have been used in the synthesis of various pharmaceuticals and chemicals, but they are not typically associated with any specific medical condition or treatment. If you have encountered the term "malonates" in a medical context, it may be helpful to provide more information or seek clarification from the source.
Hyperinsulinism is a medical condition characterized by an excess production and release of insulin from the pancreas. Insulin is a hormone that helps regulate blood sugar levels by allowing cells in the body to take in sugar (glucose) for energy or storage. In hyperinsulinism, the increased insulin levels can cause low blood sugar (hypoglycemia), which can lead to symptoms such as sweating, shaking, confusion, and in severe cases, seizures or loss of consciousness.
There are several types of hyperinsulinism, including congenital forms that are present at birth and acquired forms that develop later in life. Congenital hyperinsulinism is often caused by genetic mutations that affect the way insulin is produced or released from the pancreas. Acquired hyperinsulinism can be caused by factors such as certain medications, hormonal disorders, or tumors of the pancreas.
Treatment for hyperinsulinism depends on the underlying cause and severity of the condition. Treatment options may include dietary changes, medication to reduce insulin secretion, or surgery to remove part or all of the pancreas.
Arginase is an enzyme that plays a role in the metabolism of arginine, an amino acid. It works by breaking down arginine into ornithine and urea. This reaction is part of the urea cycle, which helps to rid the body of excess nitrogen waste produced during the metabolism of proteins. Arginase is found in various tissues throughout the body, including the liver, where it plays a key role in the detoxification of ammonia.
Liver failure is a serious condition in which the liver is no longer able to perform its normal functions, such as removing toxins and waste products from the blood, producing bile to help digest food, and regulating blood clotting. This can lead to a buildup of toxins in the body, jaundice (yellowing of the skin and eyes), fluid accumulation in the abdomen, and an increased risk of bleeding. Liver failure can be acute (sudden) or chronic (developing over time). Acute liver failure is often caused by medication toxicity, viral hepatitis, or other sudden illnesses. Chronic liver failure is most commonly caused by long-term damage from conditions such as cirrhosis, hepatitis, alcohol abuse, and non-alcoholic fatty liver disease.
It's important to note that Liver Failure is a life threatening condition and need immediate medical attention.